Impact of renin–angiotensin–aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension

18 Apr

Written By CCRG

Kei Sato, Nicole White, Jonathon P. Fanning, Nchafatso Obonyo, Michael H. Yamashita, Vinesh Appadurai, Anna Ciullo, Meryta May, Elliott T. Worku, Leticia Helms, Shinichiro Ohshimo, Dafsah A. Juzar, Jacky Y. Suen, Gianluigi Li Bassi, John F. Fraser, Rakesh C. Arora on behalf of COVID-19 Critical Care Consortium Investigators. BMC Cardiovasc Disord DOI 10.1186/s12872-022-02565-1

Background: The influence of renin–angiotensin–aldosterone system (RAAS) inhibitors on the critically ill COVID19 patients with pre-existing hypertension remains uncertain. This study examined the impact of previous use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on the critically ill COVID-19 patients.

1-30

CCRG

Impact of renin–angiotensin–aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension

Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome

Non-Invasive Multimodal Neuromonitoring in Non-Critically Ill Hospitalized Adult Patients With COVID-19